Association Of Framingham Risk Score With Chronic Kidney Disease – Insight From National Health And Nutrition Examination Survey 2003-2006

Background: The objective of this study was designed to illustrate the association between cardiovascular risk factors and CKD.Methods: Subjects aged between 30 and 74 who participated in the National Health and Nutrition Examination Survey (2003-2006) were included for analysis, and Framingham risk score was calculated. Glomerular filtration rate was estimated (eGFR) by the Modification of Diet in Renal Disease (MDRD) Equation, and CKD was defined as eGFR less than 60 ml/min/1.73m2.Results: A total of 2524 men (mean age: 51±13) and 2516 women (mean age: 50±13) completed both cardiovascular risk assessment and renal function evaluation. The proportion of Mexican Hispanic, other Hispanic, whites, blacks, and other races was 20.4%, 3.1%, 51.9%, 20.4%, and 4.2%, respectively. The 10-year coronary risk, defined as high (>=20%), intermediate (10∼20%), and low (< 10%) was assigned to 374 (14.8%), 654 ( 25.9%), and 1496 (59.3%) male subjects, and to 44 (1.7%), 365 (14.5%), and 2107 (83.7%) female subjects. The crude prevalence of CKD was 5.7% in men and 7.2% in women. The markers of renal function including serum creatinine, estimate GFR, percentage of CKD, urine albumin/creatinine ratio and percentage of microalbuminuria all correlated with the degree of Framingham risk score. Male subjects in the high- and intermediate-CHD-risk group was positively associated with the risk of microalbuminuria in subjects with normal GFR ≧ 90cc/min/1.73m2 (odds ratio:, 95% CI:, p < 0.001, and OR:, 95% CI:, p < 0.001) as compared to those in the low-CHD-risk group. In the female, the odds ratio was (high risk vs. low risk, 95% CI:, p < 0.001) and (intermediate risk vs. low risk: 95% CI:, p < 0.001). Male subjects in the high- and intermediate-CHD-risk group was positively associated …Conclusion: The population-based cohort has demonstrated that Framingham risk score could be used as a potential predictor not only for future CHD but also for concurrent CKD